Atherosclerosis. Supplements最新文献

{"title":"Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia","authors":"Viktoria Korneva ,&nbsp;Tatiana Kuznetsova ,&nbsp;Ulrich Julius","doi":"10.1016/j.atherosclerosissup.2019.08.029","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.029","url":null,"abstract":"<div><p>Familial hypercholesterolemia (FH) is associated with a very high risk of cardiovascular complications and the need for an early aggressive lipid-lowering therapy. The achievement of lipid target levels is often an extremely difficult task in these patients.</p></div><div><h3>Aims</h3><p><span>to analyze sex and age structure of ischemic heart disease (IHD) </span>in patients<span> with a definite, possible and probable FH. to assess the degree of achievement of low density lipoprotein cholesterol (LDL-C) target levels in FH patients on statin therapy and complications that occur during therapy; to analyze the adherence of FH patients to statin therapy and reveal the factors which have an influence on it.</span></p></div><div><h3>Materials and methods</h3><p>The analysis of IHD clinical characteristics was performed in 253 FH patients from Karelian register, mean age 52.5 years (confidence interval, CI 22.0; 78.0). Using Dutch Lipid Clinic Network Criteria (DLCN), we established the diagnosis of FH as “definite” if the total number of points was more than eight, “probable” – if the number of points was 6–8, “possible” if the number of points was 3–5. The diagnosis was considered to be excluded if the score was less than three. A definite FH was diagnosed in 96 patients.</p><p>For the evaluation of target LDL-C levels achievement on statin therapy we analyzed data from 191 FH patients (75 males). For the evaluation of adherence to statin therapy Morisky-Green questionnaire was used in 93 definite FH patients.</p></div><div><h3>Results</h3><p>In the group with a definite FH the incidence of IHD in the age range from 39 to 60 years was higher in women than in men (50% and 39.4%, p &gt; 0.05), in patients older than 60 years IHD was observed in 66.7% of women and 50% of men (p &gt; 0.05). In general, in the group with a definite FH, the frequency of IHD was more than three times higher in the age group over 40 years compared with patients under 40 years.</p><p>57% of patients with a definite FH were adherent to lipid-lowering therapy, 16% had partial adherence and no adherence to therapy was documented in 27% of patients. The achievement of LDL-C target levels was 19.2%: 22.6% in definite FH group and 12.5% in possible FH.</p><p>Smoking and gender were not associated with adherence to statin therapy. Associated factors with increased adherence to statin therapy were age (p = 0.000003), arterial hypertension (OR = 1.90 (1.02; to 3.55), p = 0.044), the history of IHD (OR = 2.99 (1.50; of 5.97) p = 0.002), myocardial infarction (OR = 5.26 (2.03; 13.60), p = 0.0006), myocardial revascularization (OR = 20.3 (2.64; 156.11), p = 0.004) and the fact of target LDL-cholesterol levels achievement (OR = 19.93 (7.03; 56.50), p &lt; 0.0001).</p><p><span>The main reason for the non-acceptance of statin therapy for FH patients was the fear of side effects in 87%. The main reasons for stopping current statin intake were myalgia in 12%, an increase in </span>t","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"40 ","pages":"Pages 79-87"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73494010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion","authors":"Claudius Speer ,&nbsp;Florian Kälble ,&nbsp;Luiza Pego da Silva ,&nbsp;Christian Nusshag ,&nbsp;Matthias Schaier ,&nbsp;Luis E. Becker ,&nbsp;Katrin Klein ,&nbsp;Jörg Beimler ,&nbsp;Claudia Sommerer ,&nbsp;Albrecht Leo ,&nbsp;Caner Süsal ,&nbsp;Arianeb Mehrabi ,&nbsp;Martin Zeier ,&nbsp;Christian Morath","doi":"10.1016/j.atherosclerosissup.2019.08.030","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.030","url":null,"abstract":"<div><h3>Objective</h3><p><span>In recent studies, semi-selective compared to antigen-specific immunoadsorption<span><span> (IA) columns showed comparable effectiveness in anti-A/B antibody removal before incompatible living donor kidney transplantation<span>. Semi-selective columns allow a greater number of IA treatments at lower costs. They are also capable of removing potentially harmful </span></span>human leukocyte antigen<span><span> alloantibodies. Nevertheless, additional </span>plasma exchange treatments are often necessary to reach the preoperative target titer, most likely due to an inadequate anti-A/B </span></span></span>IgM antibody depletion.</p></div><div><h3>Methods</h3><p>We compared the effectiveness of immunoglobulin and anti-A/B antibody reduction by different semi-selective (Therasorb Ig-flex, Therasorb Ig-omni5, Immunosorba) and antigen-specific (Glycosorb) IA columns during the desensitization of 63 ABO-incompatible living donor kidney transplant candidates with a total of 375 IA treatments. Fifty-three patients were eventually transplanted.</p></div><div><h3>Results</h3><p>Total IgM reduction during the first IA treatment was significantly greater with the Therasorb Ig-omni5 compared to the Therasorb Ig-flex (mean: −71.3 vs −41.6; p = 0.001) or Immunosorba columns (mean: −71.3 vs −42.8; p = 0.03). During a median of 5.5–6 pre-transplant IA treatments, Therasorb Ig-flex and Therasorb Ig-omni5 columns were equally effective in the reduction of total IgM while both showed superior IgM reduction compared to the Immunosorba columns (Therasorb Ig-flex, mean: −81.2 vs −72.2; p = 0.01; Therasorb Ig-omni5, mean: −88.2 vs −72.2; p = 0.02). IgG reduction was not significantly different between groups. Likewise, anti-A/B IgM antibody reduction (titer Saline) during the first IA treatment was significantly greater with the Therasorb Ig-omni5 compared to the Therasorb Ig-flex (mean titer reduction: −1.9 vs −1.1; p = 0.02) and tended to be greater than with Immunosorba or Glycosorb columns. During a median of 5–6 pre-transplant IA treatments, overall anti-A/B IgM antibody reduction was significantly greater when IA was performed with the Therasorb Ig-flex (mean titer reduction: −3.8 vs −1.3; p &lt; 0.001) or Therasorb Ig-omni5 (mean titer reduction: −4.3 vs −1.3; p = 0.01) compared to the Immunosorba columns with no differences compared to the Glycosorb columns. Again, anti-A/B IgG antibody reduction (titer Coombs) was not significantly different between groups.</p></div><div><h3>Conclusions</h3><p>The semi-selective Therasorb Ig-omni5 device offers potential advantages in reducing total IgM as well as anti-A/B IgM antibodies.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"40 ","pages":"Pages 68-72"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84539828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying 25% Of Individuals With Fh In The Next 5 Years: Is This An Achievable Target?","authors":"K. Haralambos * ,&nbsp;J. Whitmore ,&nbsp;I. McDowell ,&nbsp;S. Humphries","doi":"10.1016/j.atherosclerosissup.2019.08.008","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.008","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Page e4"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49188765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring Pcsk9 Levels Prior To Commencement Of Treatment To Investigate The Varied Response To Pcsk9 Therapy","authors":"K. Peers * ,&nbsp;H. Wiggins ,&nbsp;S. Ramachandran ,&nbsp;A. Jones","doi":"10.1016/j.atherosclerosissup.2019.08.006","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.006","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Page e3"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46896855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S1567-5688(19)30069-8","DOIUrl":"https://doi.org/10.1016/S1567-5688(19)30069-8","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Page e1"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1567-5688(19)30069-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138382203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolocumab therapy and a possible association with skin reactions","authors":"A. Ragavan,&nbsp;A. David,&nbsp;J. Scott,&nbsp;S. Walji,&nbsp;J. Cegla *","doi":"10.1016/j.atherosclerosissup.2019.08.015","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.015","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Page e7"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47820742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes In Serum Triglycerides Are Associated With Improvements In Small Fibre Neuropathy In Obese Persons Following Bariatric Surgery","authors":"S. Adam ,&nbsp;S. Azmi ,&nbsp;Y. Liu ,&nbsp;M. Ferdousi ,&nbsp;T. Siahmansur ,&nbsp;A. Kalteniece ,&nbsp;A. Marshall ,&nbsp;J. Ho ,&nbsp;Z. Iqbal ,&nbsp;S. Dhage ,&nbsp;Y. D'Souza ,&nbsp;S. Natha ,&nbsp;P. Kalra ,&nbsp;R. Donn ,&nbsp;A. Syed ,&nbsp;B. Ammori ,&nbsp;P. Durrington ,&nbsp;R. Malik ,&nbsp;H. Soran","doi":"10.1016/j.atherosclerosissup.2019.08.005","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.005","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Page e3"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41812968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three years experience of lomitapide therapy in the uk","authors":"J. Cegla,&nbsp;S. Walji,&nbsp;C. Neuwirth,&nbsp;L. Barton,&nbsp;G. Thompson,&nbsp;J. Scott","doi":"10.1016/j.atherosclerosissup.2019.08.014","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.014","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Pages e6-e7"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48677612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic testing for familial hypercholesterolaemia, are we testing the right patients?","authors":"S. Haslam * ,&nbsp;L. Salazar ,&nbsp;R. Allcock","doi":"10.1016/j.atherosclerosissup.2019.08.017","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.017","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Pages e7-e8"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45348074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"12 Month Review Of Lipid / Cholesterol Testing Throughout North Wales (Betsi Cadwaladr University Health Board) – An Adjunct For Familial Hypercholesterolaemia (Fh) Case Finding","authors":"R. Gingell * ,&nbsp;Y.P. Teoh ,&nbsp;M. Shah ,&nbsp;P. Wainwright ,&nbsp;G. Davies","doi":"10.1016/j.atherosclerosissup.2019.08.007","DOIUrl":"10.1016/j.atherosclerosissup.2019.08.007","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":"38 ","pages":"Pages e3-e4"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2019.08.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42373848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}